v3.26.3
Segment Information
 3 Months Ended
Mar. 31, 2026
Segment Reporting [Abstract]  
Segment Information

20. Segment Information

 

There have been no material changes in the Company’s segments since December 31, 2025, except as disclosed below. Refer to Note 17 – Segment Information in the Company’s 2025 Annual Report on Form 10-K for additional information and definitions of certain terms used in this Note.

 

 

Financial information by segment for the three months ended March 31, 2026 and 2025 is as follows:

 

   Cell Therapy   BioBanking   Degenerative Disease   Other   Total 
   3 Months Ended March 31, 2026 
   Cell Therapy   BioBanking   Degenerative Disease   Other   Total 
Net revenues  $493   $1,250   $2,103   $-   $3,846 
Cost of revenues   -    222    1,230    -    1,452 
Direct expenses   2,467    243    1,588    7,861    12,159 
Segment contribution  $(1,974)  $785   $(715)  $(7,861)  $(9,765)
Indirect expenses (a)                       368 
Loss from operations                      $(10,133)
Other income, net                      $11,007 
Income before income taxes                      $874 

 

(a)Comprised of amortization of intangible assets.

 

   Cell Therapy   BioBanking   Degenerative Disease   Other   Total 
   3 Months Ended March 31, 2025 
   Cell Therapy   BioBanking   Degenerative Disease   Other   Total 
Net revenues  $264    1,408    9,754   $-    11,426 
Cost of revenues (excluding amortization of acquired intangible assets)        209    3,345    -    3,554 
Direct expenses   3,257    369    4,747    9,617    17,990 
Segment contribution  $(2,993)   830    1,662   $(9,617)  $(10,118)
Indirect expenses (a)                      $368 
Loss from operations                      $(10,486)
Other expenses                      $(9,268)
Loss before income taxes                      $(19,754)

 

(a)Comprised of amortization of intangible assets.